Drug Topics September 19, 2024
Peter Wehrwein

Following the Federal Trade Commission’s interim report on PBMs, legislators are galvanized to make change happen.

It is “highly likely” that pharmacy benefit management (PBM) legislation will cross the legislative finish line this year, according to Patrick Cooney, president of The Federal Group, a Washington, DC-based lobbying firm. Cooney was interviewed during the 2024 Pharmacy Benefit Management Institute Annual National Conference by Drug Topics’ sister publication, Managed Healthcare Executive, where he discussed the role of the Federal Trade Commission (FTC) interim report in galvanizing legislators, as well as his predictions on what provisions the potential PBM legislation might contain.

What are the chances that Congress will pass PBM legislation this year?

Patrick Cooney: I think the prospects are high. After...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Congress / White House, Govt Agencies, Interview / Q&A, Pharma, Pharma / Biotech, Trends
How Digital Chemistry Will Improve Cross-Functional Collaboration In The Biopharma Industry
Survey Suggests Pharma Industry Still Struggling with Digital Transformation
Will Walgreens’ store closures disrupt its clinical trial aims?
340B Legal Challenges Highlight The Appetite For Innovation That Supports The Program’s Goals
How Agencies Should Decide Which Costly Drugs To Target With Government March-In Rights

Share This Article